{"id":"benralizumab-arm-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benralizumab targets the interleukin-5 (IL-5) receptor alpha subunit, which is expressed on eosinophils and basophils. By blocking this receptor, the drug prevents IL-5 signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid depletion of these immune cells. This mechanism reduces eosinophilic inflammation in the airways, making it effective for eosinophilic asthma and other eosinophil-driven conditions.","oneSentence":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduced airway inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:05.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe eosinophilic asthma"},{"name":"Severe asthma with eosinophilic phenotype"}]},"trialDetails":[{"nctId":"NCT04612725","phase":"PHASE2","title":"A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-10-27","conditions":"Chronic Spontaneous Urticaria","enrollment":159},{"nctId":"NCT06288516","phase":"PHASE4","title":"BenRalizumab Effect on Airway Remodeling in Severe asTHma","status":"RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2024-03-01","conditions":"Asthma; Eosinophilic, Airway Remodeling","enrollment":45},{"nctId":"NCT02808819","phase":"PHASE3","title":"A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Asthma","enrollment":447},{"nctId":"NCT02258542","phase":"PHASE3","title":"A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-19","conditions":"Asthma","enrollment":2133},{"nctId":"NCT02155660","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-25","conditions":"Moderate to Very Severe Chronic Obstructive Pulmonary Disease","enrollment":2255},{"nctId":"NCT02138916","phase":"PHASE3","title":"Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-13","conditions":"Moderate to Very Severe Chronic Obstructive Pulmonary Disease","enrollment":1656},{"nctId":"NCT02075255","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-28","conditions":"Asthma","enrollment":220},{"nctId":"NCT02322775","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-02","conditions":"Asthma","enrollment":211}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Benralizumab Arm B","genericName":"Benralizumab Arm B","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduced airway inflammation. Used for Moderate-to-severe eosinophilic asthma, Severe asthma with eosinophilic phenotype.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}